大剂量瑞舒伐他汀钙治疗老年冠心病合并高脂血症的疗效观察  

Efficacy of High-dose of Rosuvastatin Calcium in Treatment of Elderly Coronary Heart Disease and Hyperlipidemia

作　　者：彭道地[1] 刘琼[1] 谢伟[1] 余再新[1] 邹鹏 

机构地区：[1]中南大学湘雅医院心内科,湖南长沙410008 [2]永州市第四人民医院内二科,湖南永州425006

出　　处：《现代生物医学进展》2015年第31期6068-6070,共3页Progress in Modern Biomedicine

摘　　要：目的:研究大剂量瑞舒伐他汀钙治疗老年冠心病合并高脂血症的临床疗效。方法:选取2013年10月到2014年10月我院收治的老年冠心病合并高脂血症患者110例,按照随机数字表法将患者分为研究组和对照组,每组55例。两组患者均给予常规治疗方法进行治疗,对照组增加5 mg瑞舒伐他汀钙进行治疗,研究组增加20 mg瑞舒伐他汀钙进行治疗,均每天1次,晚餐后应用,治疗时间为4个月。比较治疗前后两组血脂水平(胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白(LDL-C))及高密度脂蛋白(HDL-C)及其达标率以及不良反应。结果:治疗后两组TC、TG以及LDL-C均显著降低,HDL-C显著升高,且研究组优于对照组,比较差异具有统计学意义(P<0.05);研究组治疗后TC和LDL-C达标率显著高于对照组,两组比较差异具有统计学意义(P<0.05);两组不良反应发生率比较差异无统计学意义(P>0.05)。结论:大剂量瑞舒伐他汀钙治疗老年冠心病合并高脂血症具有较好的临床疗效,能显著降低患者的血脂水平。Objective： To study the clinical efficacy of high-dose of rosuvastatin calcium in treatment of elderly coronary heart disease and hyperlipidemia. Methods： 110 elderlys with coronary heart disease and hyperlipidemia were selected from our hospital from October 2013 to October 2014, who were divided into study group and the control group according to the random number table method,with 55 patients in each group. All patients were treated with conventional therapy, then the control group was added 5mg rosuvastatin calcium, while the study group was added 20 mg rosuvastatin calcium, rosuvastatin calcium in two groups were 1 time a day after dinner,and lasted for 4 months.Compare the blood lipid level（including cholesterol（TC） and triglyceride（TG）, low density lipoprotein（LDL-C））,high density lipoprotein（HDL-C））, their up to the standard rate, and adverse reactions of two groups before and after treatment. Results：TC, TG and LDL-C levels of two groups after treatment were significantly lower than before treatment, but HDL-C was significantly increased after treatment, and the improvement of study group was better than control group, the differences were statistically significant（P〈0.05）; TC and LDL-C up to the standard rate of study group after treatment were significantly higher than control group, the difference was statistically significant（P〈0.05）; However, the incidence of adverse reactions of two groups was not significant difference（P〉0.05）. Conclusion： High-dose of rosuvastatin calcium in treatment of elderly coronary heart disease and hyperlipidemia has better clinical efficacy, which can significantly cut down the blood lipid level.

关 键 词：瑞舒伐他汀钙 冠心病 高脂血症 疗效 

分 类 号：R541.4[医药卫生—心血管疾病]